In major move, patent of Novartis' blockbuster cardiac drug revoked by IndiaThe Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decis...
Novartis to buy Tourmaline Bio for $1.4 billionNovartis AG is set to acquire Tourmaline Bio for $1.4 billion, aiming to bolster its drug pipeline amid upcoming generic competition for ke...
Aditya Khemka on US tariff threat over pharma and what to bet on thereInCred Asset Management is cautious about US-facing generic pharma companies due to potential tariff risks and single-digit earnings growth...
Hot Stocks: Brokerage view on Godrej Properties & Divi’s Lab; CLSA initiates coverage on SwiggyLeading brokerages are bullish on several key stocks. CLSA initiates coverage on Swiggy with a "Buy" rating, projecting a 31% upside. Jeffe...
Divi's Lab stock slips on US supply worries"While the exact revenue from Entresto-related supplies is undisclosed, it contributes a meaningful share to the overall business. However,...
Indian CDMO players poised for global leadership, says Emkay’s Sachin ShahAnd, of course, the chemical in terms of the domain expertise, the kind of the chemistry skills and the overall talent pool that this count...
Hot Stocks: Brokerage firms see 15-24% upside in Zomato, Divi’s Laboratories & Allied BlendersTop brokerages ICICI Securities, Citi, and Jefferies recommend Allied Blenders, Divi’s Laboratories, and Zomato, highlighting growth in pre...
Novartis CEO 'very confident' on sales target, doesn't fear patent cliffNovartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday.
Natco Plea: Delhi high court sets aside Novartis patentNatco filed writ petition citing procedural irregularities and violation of principles of natural justice by the Assistant Controller of Pa...
HC reserves order on Natco's plea over patent for Novartis drugNatco has argued before Justice C Hari Shankar against the grant of patent by IPO to the pharmaceutical composition comprising combination ...
Natco dares Novartis with new heart drugAccording to data from AIOCD PharmaTrac, an agency that closely tracks pharmaceutical sales, Vymada had sales of Rs 68.3 crore for December...
European shares buoyed by tech, pharma stocks; Fiat, Bayer slumpThe pan-European FTSEurofirst 300 index, which had risen 1.3 percent in the previous session, was up 0.2 percent at 1,329.6 points by 0820 ...
Novartis gets USFDA nod for heart failure drugThe Swiss drug major said the USFDA's decision was based on results of a study on 8,442 patients, including 637 from India.